Semaglutide in CFRD

NCT05788965 · Completed

Last updated 2026-05-28

This clinical trial is testing whether semaglutide, a medication, can help people with cystic fibrosis-related diabetes maintain or gain weight.

Status Completed The study has finished.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 8 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-10 · est. completion 2024-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05788965 ↗

Description as written by the study sponsor.

This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).

Treatments tested

Semaglutide also known as GLP-1 RA, Semaglutide Injectable Product Drug

glucagon-like peptide 1 (GLP-1) receptor agonist

Main thing measured	Weight
Sponsor	University of Minnesota
Conditions studied	Cystic Fibrosis, Cystic Fibrosis-related Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05788965 ↗